Format

Send to

Choose Destination
See comment in PubMed Commons below
Respir Med. 2006 May;100(5):765-74. Epub 2006 Mar 23.

Treatments for pulmonary arterial hypertension.

Author information

1
The First Hospital of Hebei Medical University, Hebei Medical University, 89 Donggang Road, Shijiazhuang, Hebei Province 050031, People's Republic of China. dr_chaoliu@yahoo.com.cn

Abstract

Pulmonary arterial hypertension (PAH) is a devastating disease that leads to right heart failure and premature death. Historically, we are restricted by limited options for drug treatment. Over the past decade, with advances in our understanding of pathophysiological and molecular mechanisms, many new therapeutic strategies (synthetic prostacyclin and prostacyclin analogues, endothelin receptor antagonists and sildenafil) have been developed for the treatment of PAH, and the clinical efficacy has been tested in many randomized-controlled trials (RCTs). In this overview, we review the evidence for the use of historical and new treatments that arises from the Cochrane Collaboration of Systematic Reviews and from recent RCTs.

PMID:
16549344
DOI:
10.1016/j.rmed.2006.01.021
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center